Bio Pharma Dive

MAY 3, 2024

The company said data for its Wegovy competitor was promising enough to move the drug into late-stage testing, triggering a stock jump that added billions to Amgen’s market value.

Drugs 277

Drugs Marketing 277

Bio Pharma Dive

JULY 9, 2024

On Tuesday, regulators updated the public on their yearslong probe of PBM's business practices. The report faults PBMs for profiting at the expense of patients and independent pharmacists.

Marketing 139

Marketing Regulation Drugs 139

Pharmaceutical Technology

OCTOBER 25, 2023

Experts discuss the key trends in quality improvements and API reshoring for the generic drugs market at CpHI Europe.

Generic Drugs 147

Generic Drugs Marketing Drugs 147

Bio Pharma Dive

JULY 10, 2024

Having recently withdrawn its only product from the market, Amylyx hopes to rebound with a drug that regulates GLP-1 activity and is poised to enter pivotal testing early next year.

Drugs 188

Drugs Regulation Production Marketing 188

Fierce Pharma

APRIL 4, 2024

Amylyx Pharmaceuticals is keeping a promise by pulling the amyotrophic lateral sclerosis (ALS) therapy Relyvrio off the market after the drug failed in a confirmatory trial. Amylyx is keeping a promise by pulling the amyotrophic lateral sclerosis (ALS) therapy Relyvrio off the market after the drug failed in a confirmatory trial.

Marketing 116

Marketing Drugs Trials 116

Pharmaceutical Technology

JANUARY 23, 2023

As such, the SLE and LN marketplace is dominated by generics, and GSK’s Benlysta and AstraZeneca’s Saphnelo are the only drugs that have gained marketing approval specifically for SLE in more than 50 years. In previous years, Benlysta has managed to grow the lupus market in terms of value, having generated approximately $492.9m

Marketing 278

Marketing Production Drugs Trials 278

Pharmaceutical Technology

DECEMBER 5, 2023

Professor Timothy Mackey talks about the recent reports of fraudulent Ozempic pens and the challenges in chasing drug counterfeiters.

Drugs 278

Drugs Marketing 278

Fierce Pharma

APRIL 23, 2024

The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales. | The orphan drug sector has long been clearing growth in the larger pharmaceutical market with booming sales.

Marketing 110

Marketing Sales Drugs 110

BioSpace

MAY 14, 2024

Crackdowns on drug pricing have forced one major insulin out of the market. Are more to come?

Insulin 110

Insulin Marketing Sales Drugs 110

Pharmaceutical Technology

SEPTEMBER 1, 2023

Novo Nordisk's obesity drugs are driving Danish growth as well as record profits as the company becomes second-most valuable in Europe.

Drugs 264

Drugs Marketing 264

World of DTC Marketing

APRIL 20, 2022

We just finished talking to over 200 hundred HCPs about pharma marketing and salespeople to measure any differences since before the pandemic. This was especially true with new drugs that have a significant competitive market. Will they transform their HCP marketing or stick to dated models?

Marketing 218

Marketing Drug Trials Drugs Sales 218

Pharmaceutical Technology

JUNE 12, 2023

Lotus Pharmaceuticals and Teraju Pharma have entered a strategic partnership to market Lotus’s products in a range of therapeutic areas in Malaysia. Teraju Pharma will be responsible for marketing and promoting the products using its relationships and infrastructure.

Marketing 242

Marketing Production Branding Manufacturing 242

Pharmaceutical Technology

NOVEMBER 14, 2022

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Oncopeptides’ Pepaxti (melphalan flufenamide; melflufen) along with dexamethasone to treat multiple myeloma patients. Currently, the company is analysing Pepaxti’s market access options in the country.

Marketing 130

Marketing Drugs Clinical Trials Clinical Trials 130

Pharmaceutical Technology

FEBRUARY 23, 2024

The FDA Office of Generic Drugs reported a rise in generic drug approvals, as several first-time generics entered the market.

Generic Drugs 263

Generic Drugs Drugs Marketing 263

Pharmaceutical Technology

APRIL 5, 2024

Last month, Amylyx announced that the Phase III confirmatory trial of ALS drug Relyvrio failed to meet its primary and secondary endpoints.

Drugs 130

Drugs Marketing Trials 130

BioSpace

APRIL 3, 2024

Following disappointing late-stage data, Amylyx on Thursday said it is withdrawing the company’s amyotrophic lateral sclerosis drug Relyvrio from the U.S. and Canadian markets and cutting its workforce by approximately 70%.

Marketing 108

Marketing Drugs 108

pharmaphorum

JULY 19, 2024

Less than two years after pulling multiple myeloma therapy Blenrep off most markets around the world, GSK has filed for approval of the drug in the EU once again, hoping to restore its blockbuster credentials.The remarkable renaissance for the BCMA-directed antibody-drug conjugate is supported by a pair of phase 3 trials that could not only support (..)

Marketing 86

Marketing Antibody Trials Drugs 86

Bio Pharma Dive

OCTOBER 6, 2022

The pharma will invest in the biotech and co-promote its drug teplizumab if the FDA OKs the medicine as a first-of-its-kind diabetes treatment.

Drugs 272

Drugs Marketing Medicine 272

Drug Discovery World

FEBRUARY 26, 2024

The global ADME toxicology testing market is predicted to generate a revenue of $19.21 Factors such as an increased need to check late-stage drug failures with the adoption of more appropriate toxicity testing methods by pharmaceutical companies are expected to aid revenue generation for the market.

Marketing 59

Marketing Drugs Development 59

pharmaphorum

APRIL 4, 2024

Amylyx confirmed today that it will withdraw its amyotrophic lateral sclerosis (ALS) therapy Relyvrio/Albrioza from the market in the US and Canada, shortly after the drug failed a clinical trial.

Marketing 85

Marketing Drugs Doctors Doctor 85

Pharmaceutical Technology

MARCH 27, 2024

The market for multiple sclerosis therapies is expected to be worth over $41bn by 2030, according to GlobalData.

Marketing 130

Marketing Licensing Licensing Drugs 130

Fierce Pharma

MARCH 8, 2024

After reporting the failu | After reporting the failure of a confirmatory trial of its amyotrophic lateral sclerosis drug Relyvrio (AMX0035), Amylyx Pharmaceuticals is uncertain whether it will pull the treatment from the market in the U.S. and in Canada, where it is known as Albrioza.

Marketing 95

Marketing Trials Drugs 95

Drug Patent Watch

OCTOBER 2, 2023

The FDA conducted a study to identify factors that may predict the likelihood of generic drug marketing applications.

Generic Drugs 111

Generic Drugs Marketing Drugs 111

pharmaphorum

JUNE 27, 2024

Verona Pharma has claimed FDA approval for its chronic obstructive pulmonary disease (COPD) drug ensifentrine, which has been tipped as a future blockbuster.The first-in-class dual phosphodiesterase (PDE) 3/4 inhibitor – now given the somewhat tongue-twisting brand name of Ohtuvayre – is the first inhaled product with a novel mechanism of action available (..)

FDA Approval 94

FDA Approval Marketing Drugs Branding 94

Fierce Pharma

SEPTEMBER 7, 2023

Demand is so strong for Novo Nordisk’s obesity drugs that the only limitation on sales—in the short term—seems to be the company’s ability to produce them. Morgan, which has doubled its market projection for GLP-1 diabetes and obesity treatments to $71 billion for 2032.

Marketing 134

Marketing Drugs Sales 134

pharmaphorum

MAY 21, 2024

Going against the advice of the CHMP, the EU has said that PTC Therapeutics’ Translarna therapy for Duchenne muscular dystrophy should stay on the market

Marketing 98

Marketing Drugs 98

pharmaphorum

JUNE 5, 2024

KRAS inhibitors from Eli Lilly, Genfleet, and InxMed make their case for use in NSCLC at ASCO, as they case down Amgen and Bristol-Myers Squibb's market drugs

Marketing 108

Marketing Drugs 108

Outsourcing Pharma

SEPTEMBER 29, 2023

Chinese biopharmaceutical company, Hutchmed Limited, has announced today (Friday September 29) that it has taken a step towards bringing a colon and rectum cancer drug to a third market.

Marketing 96

Marketing Drugs Clinical Development Development 96

BioSpace

MAY 28, 2024

Driven by growing market demand and an improving supply chain, the global weight-loss drug market is expected to hit $150 billion in value by the early 2030s, according to analysts cited by Reuters.

Marketing 108

Marketing Drugs 108

BioSpace

JUNE 13, 2024

While GLP-1 drugs remain wildly popular and are a highly lucrative sector, data analytics firm GlobalData contends manufacturing and cost will remain overhangs on the obesity market.

Marketing 118

Marketing Manufacturing Drugs 118

BioSpace

JULY 7, 2024

With the antibody drug conjugate market projected to hit $28 billion by 2028, some companies are looking to harness the drugs for immunotherapy.

Drugs 120

Drugs Development Antibody Marketing 120

Drug Discovery World

JUNE 1, 2023

Antibody-drug conjugates (ADCs) are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker 1. A Nature publication confirmed that there are currently 12 FDA-approved ADCs on the market, and nine of these secured FDA approval in the past six years 2.

Antibody 98

Antibody Marketing Drugs Licensing 98

XTalks

OCTOBER 4, 2023

Health economics and outcomes research (HEOR) and market access strategies play a critical role in ensuring that newly approved therapies are made available to patients. Professionals in these roles are facing new challenges when it comes to negotiating coverage for many of the new, innovative treatments that are coming to market.

Marketing 105

Marketing Development Drugs Gene Therapy 105

Drug Discovery World

FEBRUARY 20, 2024

The drug discovery informatics market is predicted to grow from $3.77 The new report says the anticipated growth to 2028 will be fuelled by the expansion of precision medicine, advancements in drug-drug interaction prediction, analysis of patient-derived data, development of biosimilars, and the increasing number of drug candidates.

Marketing 52

Marketing Drugs Life Science Genome 52

Medical Xpress

MARCH 16, 2023

An animal tranquilizer has flooded the illicit drug market in Maryland, according to a new study by the National Institute of Standards and Technology (NIST) and the Maryland Department of Health.

Marketing 98

Marketing Drugs 98

Drug Patent Watch

JUNE 27, 2024

Introduction Patent portfolios are critical assets for pharmaceutical companies, providing market exclusivity and protecting revenue streams for drug products. Effective management of drug patent portfolios requires strategic planning, ongoing evaluation, and adaptation to the evolving pharmaceutical landscape.

Drugs 105

Drugs Production Marketing 105

BioSpace

JUNE 23, 2024

Altimmune Targets Obesity Market With Weight-Loss Drug That Preserves Lean Muscle Mass 6/24/2024

Marketing 57

Marketing Drugs 57